Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
7 enrolled 14 charts
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Phase 1 Completed
10 enrolled
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Phase 2 Completed
78 enrolled
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
Phase NA Completed
114 enrolled
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
Phase 2 Completed
20 enrolled 13 charts
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Phase 4 Completed
81 enrolled 15 charts
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 2 Completed
42 enrolled
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Completed
260 enrolled 52 charts
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Phase 1 Completed
112 enrolled
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Phase NA Completed
8 enrolled
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
44 enrolled
KEYNOTE-B84
Phase 1/2 Completed
49 enrolled
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Phase 1 Completed
48 enrolled
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1 Completed
12 enrolled
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
Phase 1/2 Completed
52 enrolled
Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients
Phase NA Completed
38 enrolled
Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC
Phase 2 Completed
38 enrolled
ACTIVE
Phase 4 Completed
750 enrolled
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Phase 1 Completed
29 enrolled
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Phase 1 Completed
35 enrolled
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
109 enrolled 25 charts
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Phase 1 Completed
14 enrolled 13 charts
UNN-RADS Scale for Diagnosing Lymph Node Metastasis in Patients With History of Thyroid Cancer
Completed
99 enrolled
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 2 Completed
153 enrolled
Parsabiv-MBD
Phase 2 Completed
22 enrolled 14 charts
Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
Phase 2 Completed
40 enrolled
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
Phase 1 Completed
36 enrolled
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
Phase 1 Completed
12 enrolled
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Phase 1 Completed
13 enrolled 10 charts
ABORL
Phase 2 Completed
25 enrolled
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Phase 1 Completed
15 enrolled
Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma
Phase 3 Completed
104 enrolled
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Phase 2 Completed
52 enrolled 17 charts
ELANFIT
Phase 2 Completed
85 enrolled
Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)
Completed
18 enrolled
VOLUME-PRO
Completed
509 enrolled
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Phase 1 Completed
174 enrolled 68 charts
First-in-human Study of S-588210 (S-488210+S-488211)
Phase 1 Completed
10 enrolled
NISCAHN
Phase 2 Completed
98 enrolled
A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe
Completed
304 enrolled
SPICE
Phase 1 Completed
51 enrolled
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Phase 1 Completed
118 enrolled
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Phase 1 Completed
168 enrolled 59 charts
Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment
Phase NA Completed
40 enrolled
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Phase 1 Completed
22 enrolled
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Phase 2 Completed
14 enrolled 17 charts
Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1 Completed
10 enrolled
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
Phase 2 Completed
80 enrolled
PIK-ORL
Phase 2 Completed
58 enrolled